NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 14 October 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John [Topic 1 Chair] Items 1 to 4.2.2 & 5.1.3 to 6.2.2
2. Dr Lindsay Smith [Topic 2 Chair] Items 1 to 5.2.2
3. Professor Stephen O’Brien [Topic 3 Chair] Items 6 to 6.2.2
4. Martin Bradley Present for all items
5. Dr Matthew Bradley Items 5 to 6.2.2
6. Dr Charles Crawley [non-voting member] Items 5 to 6.2.2
7. Professor Sofia Dias Present for all items
8. Professor Rachel Elliott Items 1 to 4.2.2 & 5.1.3 to 6.1.3
9. Chris Herring Present for all items
10. Dr Andrew Hitchings Present for all items
11. Dr Robert Hodgson Present for all items
12. Dr Bernard Khoo Items 1 to 4.2.2 & 6 to 6.2.2
13. Dr Soo Fon Lim Present for all items
14. Dr Guy Makin Present for all items
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Malcolm Oswald Present for all items
18. Dr Rebecca Payne Items 1 to 5.2.2 & 6.1.3 to 6.2.2
19. Professor Chris Parker Present for all items
20. Carole Pitkeathley [non-voting member] Present for all items
21. Baljit Singh Items 1 to 4.2.2 & 5.1.3 to 6.2.2
22. Professor John Watkins Items 1 to 4.2.2 & 6 to 6.2.2
23. Dr Ed Wilson Items 1 to 4.2.2 & 6 to 6.2.2

NICE staff present

Helen Knight, Programme Director  Items 6 to 6.2.2

Linda Landells, Associate Director Items 1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5 to 5.2.2

Ross Dent, Associate Director Items 6 to 6.2.2

Kate Moore, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Gavin Kenny, Project Manager Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 1 to 4.1.3 & 6 to 6.2.2

Charlie Hewitt, Health Technology Assessment Adviser Items 1 to 4.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 5 to 5.2.2

Sally Doss, Health Technology Assessment Adviser Items 6 to 6.2.2

Zain Hussain, Health Technology Assessment Analyst Items 1 to 4.2.2

Victoria Gillis-Elliott, Health Technology Assessment Analyst Items 5 to 5.2.2

Elizabeth Bell, Health Technology Assessment Analyst Items 6 to 6.2.2

Ziqi Zhou, Associate Health Technology Assessment Analyst Items 1 to 4.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 1 to 4.2.2

Emily Eaton Turner, Technical Analyst, Evidence Generation Items 5 to 5.2.2

Stephen Norton, Technical Analyst, Managed Access Team Items 6 to 6.2.2

Catrin Austin, Technical Analyst, Methods and Economics Team Items 1 to 5.2.2

Maroulla Whiteley, Senior Business Analyst, RIA Items 1 to 5.2.2

Benjamin Gregory, Senior Business Analyst, RIA, Items 6 to 6.2.2

Ruth Melville, Senior Medical Editor Items 1 to 4.2.2 & 6 to 6.2.2

Benjamin Pearce, Senior Medical Editor Items 5 to 5.2.2

Mandy Tonkinson, Public Involvement Adviser Items 1 to 4.2.2

Gemma Smith, Coordinator, COT Present for all items

Lyn Davies, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Rosalee Mason, Coordinator, MIP Items 5 to 5.1.3

Celia Mayers, Administrator, TA Items 1 to 4.2.2

Ismahan Abdullah, Administrator, TA Items 5 to 5.2.2

Iain Cannell, Administrator, TA Items 6 to 6.2.2

External review group representatives present

Paul Tappenden, School of Health and Related Research [ScHARR], Items 1 to 4.1.3 & 5 to 5.1.3

Aline Navega-Biz, School of Health and Related Research [ScHARR], Items 1 to 4.1.3 & 5 to 5.1.3

Robert Wolff, Kleijnen Reviews Ltd  Items 6 to 6.1.3

Sabine Grimm, Kleijnen Reviews Ltd Items 6 to 6.1.3

Clinical & patient experts present

Professor James Burton, Professor of Renal Medicine and Honorary Consultant Nephrologist, clinical expert nominated by AstraZeneca, Items 1 to 4.1.3

Dr Rosa Montero, Consultant nephrologist, clinical expert nominated by The Renal Association, Items 1 to 4.1.3

Dr Andrew Lewington, Vice Chair of Guidelines Development Group, Items 1 to 4.1.3

Ann Harpur-McGrath, Patient expert nominated by Kidney Care UK, Items 1 to 4.1.3

Mark Smith, Patient expert nominated by Kidney Care UK, Items 1 to 4.1.3

Professor Peter Clark, National Clinical lead for Cancer drugs, NHSE, Items 5 to 6.2.2

Professor Richard Cowan, Consultant in Clinical Oncology, clinical expert nominated by Kyowa Kirin Ltd, Items 6 to 6.1.3

Professor Sean Whittaker, Consultant Dermatologist & Professor of Cutaneous Oncology clinical expert nominated by United Kingdom Cutaneous Lymphoma Group [UKCLG], Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee noted the minutes of the committee meeting held on Thursday 16 September 2021.

### Appraisal of dapagliflozin for treating chronic kidney disease [ID3866]

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interests as the University of Leeds has received funding from Takeda and Sanofi for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Committee member Dr Ed Wilson declared financial interests as AstraZeneca Consilient Health, Lupin Healthcare, Novartis, Pfizer, Sanofi and Takeda are or have been clients of his company in the last 3 years, but they have not worked on this appraisal.
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting.
* Committee Member Dr Matthew Bradley holds shares in the company AstraZeneca, the manufacturer of Dapagliflozin.
* It was agreed that as a direct conflict Dr Bradley would not participate on this appraisal.
* Nominated clinical expert Professor James Burton declared financial interests as he has received payments from AstraZeneca for speaker engagements, advisory panels and occasional sponsorship to educational meetings / conferences. He is a member of the Renal Association Guideline Group ‘Use of SGLT2 inhibitors in people with Chronic Kidney Disease’, which will likely publish before this technology appraisal is considered. He is the Chair of the UK Kidney Association Clinical Practice Guidelines Committee.
* It was agreed that his declarations would not prevent Professor Burton from providing expert advice to the committee.
* No further conflicts were declared for this item.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the Lead team Dr Andrew Hitchings, Malcolm Oswald, and Professor Rachel Elliott.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.
* further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10808>

### Appraisal of pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1683]

* 1. Part 1 – Open session
     1. The chair Dr Lindsay Smith welcomed the invited the national clinical lead for cancer drugs fund, external review group representatives, members of the public and company representatives from MSD.
     2. The chair asked all committee members, the national clinical lead for cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interests as the University of Leeds has received funding from Celgene and Sanofi for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Committee member Dr Ed Wilson declared financial interests as MSD is or has been clients of his company in the last 3 years and have worked on the drug named, albeit in a different indication.
* It was agreed that as a direct conflict Dr Wilson would not participate on this appraisal.
* No further conflicts were declared for this item.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session [company representatives, external review group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached through a vote by members..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10537>

### Appraisal of mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited clinical experts, the national clinical lead for cancer drugs fund, external review group representatives, members of the public and company representatives from Kyowa Kirin.
     2. The chair asked all committee members, clinical experts, the national clinical lead for cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interests as the University of Leeds has received funding from Takeda for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Committee member Dr Ed Wilson declared financial interests as Eisai, Pfizer and Takeda are or have been clients of his company in the last three years, but they have not worked on drugs related to this appraisal.
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting
* Committee Member Dr Matthew Bradley declared a non-financial interest as GSK, is in a co-marketing agreement with Kyowa Kirin for medicine in an unrelated disease area that is only available in Japan.
* It was agreed that as a direct conflict Dr Bradley would not participate on this appraisal.
* Nominated clinical expert Professor Richard Cowan declared a financial interest as he has participated in advisory groups for Kyowa Kirin and has in the past provided consultancy work for them.
* It was agreed that his declaration would not prevent Professor Cowan from providing expert advice to the committee.
* Nominated clinical expert Professor Sean Whittaker declared a non-financial interest as he has previously been invited to sit on a Kyowa Kirin advisory board.
* It was agreed that his declaration would not prevent Professor Whittaker from providing expert advice to the committee.
* No further conflicts were declared for this item.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session [company representatives, clinical experts, external review group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10305>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 11 November 2021 and will start promptly at 9.30am.